Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.
- DOI
- 10.1177/17588359261467380
- Published
- 2026
- Container
- Therapeutic advances in medical oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17588359261467380,
title = {Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.},
author = {Cottu P and Pascual T and Lemonnier J and Hu H and Roux E and Connolly RM and Ma CX and Wolff AC and Crestani T and Tolosa P and Ferrero-Cafiero JM and Mulero-Sánchez A and Salvador F and Villacampa G and Gavilá J and de La Motte Rouge T and Prat A},
year = {2026},
journal = {Therapeutic advances in medical oncology},
doi = {10.1177/17588359261467380},
url = {https://doi.org/10.1177/17588359261467380}
}RIS
TY - JOUR TI - Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer. AU - Cottu P AU - Pascual T AU - Lemonnier J AU - Hu H AU - Roux E AU - Connolly RM AU - Ma CX AU - Wolff AC AU - Crestani T AU - Tolosa P AU - Ferrero-Cafiero JM AU - Mulero-Sánchez A AU - Salvador F AU - Villacampa G AU - Gavilá J AU - de La Motte Rouge T AU - Prat A PY - 2026 JO - Therapeutic advances in medical oncology DO - 10.1177/17588359261467380 UR - https://doi.org/10.1177/17588359261467380 ER -
APA
P, C., T, P., J, L., H, H., E, R., RM, C., CX, M., AC, W., T, C., P, T., JM, F., A, M., F, S., G, V., J, G., T, D. L. M. R., & A, P. (2026). Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.. Therapeutic advances in medical oncology. https://doi.org/10.1177/17588359261467380
Source records
- pubmed · retrieved 2026-09-26T00:54:23.096Z